Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of AZD3241 in multiple system atrophy
2009-018157-23Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple system atrophy (MSA) comparing AZD3241 with Placebo (2 arms). Primary endpoint: Change in UMSARS I+II score from baseline to Month 12. Started Jun 2010; status: terminated.
02
Drugs
verdiperstat
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on 2009-018157-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-018157-23.